Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 5, 2015, Pages 201.e9-201.e16

  Langsenlehner, Tanja ^a   Pichler, Martin ^b   Thurner, Eva Maria ^a   Krenn Pilko, Sabine ^a   Stojakovic, Tatjana ^a   Gerger, Armin ^a   Langsenlehner, Uwe ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Division of Internal Medicine   (Austria)

Author keywords

Inflammation; Platelet to lymphocyte ratio (PLR); Prognosis; Prostate cancer

Indexed keywords

AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; DISTANT METASTASIS FREE SURVIVAL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SALVAGE THERAPY; SYSTEMIC THERAPY; TIME TO TREATMENT; COHORT ANALYSIS; DISEASE COURSE; EUROPE; LYMPHOCYTE; METABOLISM; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; THROMBOCYTE;

AGED; BLOOD PLATELETS; COHORT STUDIES; DISEASE PROGRESSION; EUROPE; HUMANS; LYMPHOCYTES; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84929282302     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.02.002     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Castelli T., Cimino S., Magno C., Morgia G. Molecular markers for prostatic cancer. Front Biosci 2010, 2:641-656.
3. Huang H.C., Zheng S., VanBuren V., Zhao Z. Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat 2010, 9:219-230.
4. Langsenlehner T., Langsenlehner U., Renner W., Kapp K.S., Krippl P., Hofmann G., et al. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 2008, 68:264-268.
5. McArdle P.A., Mir K., Almushatat A.S., Wallace A.M., Underwood M.A., McMillan D.C. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int 2006, 77:127-129.
6. McArdle P.A., Qayyum T., McMillan D.C. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol Int 2010, 85:482.
7. Shafique K., Proctor M.J., McMillan D.C., Qureshi K., Leung H., Morrison D.S. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis 2012, 15:195-201.
8. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
9. Szkandera J., Gerger A., Liegl-Atzwanger B., Absenger G., Stotz M., Friesenbichler J., et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 2014, 135:362-370.
10. Szkandera J., Gerger A., Liegl-Atzwanger B., Absenger G., Stotz M., Samonigg H., et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients. Br J Cancer 2013, 109:2316-2322.
11. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., Fletcher C.D., O'Reilly D.S., et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011, 47:2633-2641.
12. Krenn-Pilko S., Langsenlehner U., Thurner E.M., Stojakovic T., Pichler M., Gerger A., et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer 2014, 110:2524-2530.
13. Asher V., Lee J., Innamaa A., Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol 2011, 13:499-503.
14. Smith R.A., Bosonnet L., Raraty M., Sutton R., Neoptolemos J.P., Campbell F., et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009, 197:466-472.
15. Kwon H.C., Kim S.H., Oh S.Y., Lee S., Lee J.H., Choi H.J., et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012, 17:216-222.
16. Mohler J., Bahnson R.R., Boston B., Busby J.E., D'Amico A., Eastham J.A., et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010, 8:162-200.
17. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
18. Jaiswal M., LaRusso N.F., Burgart L.J., Gores G.J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000, 60:184-190.
19. Klinger M.H., Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002, 22:913-922.
20. Alexandrakis M.G., Passam F.H., Moschandrea I.A., Christophoridou A.V., Pappa C.A., Coulocheri S.A., et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol 2003, 26:135-140.
21. Bakewell S.J., Nestor P., Prasad S., Tomasson M.H., Dowland N., Mehrotra M., et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A 2003, 100:14205-14210.
22. Boucharaba A., Serre C.M., Gres S., Saulnier-Blache J.S., Bordet J.C., Guglielmi J., et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004, 114:1714-1725.
23. Coppinger J.A., Cagney G., Toomey S., Kislinger T., Belton O., McRedmond J.P., et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004, 103:2096-2104.
24. Smyth S.S., McEver R.P., Weyrich A.S., Morrell C.N., Hoffman M.R., Arepally G.M., et al. Platelet functions beyond hemostasis. J Thromb Haemost 2009, 7:1759-1766.
25. Dashevsky O., Varon D., Brill A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer 2009, 124:1773-1777.
26. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
27. Surcel C.I., Sooriakumaran P., Briganti A., De Visschere P.J., Fütterer J.J., Ghadjar P., et al. Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. BJU Int 2014, 10.1111/bju.12796.
28. Bobjer J., Katrinaki M., Tsatsanis C., Lundberg Giwercman Y., Giwercman A. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PLoS One 2013, 8:e61466.
29. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol 2006, 50:935-939.